Jabbit

News explainer · Sources checked October 15, 2026

Published · Updated

FDA warning letters on telehealth marketing of compounded GLP-1s

On March 3, 2026, FDA announced 30 warning letters to telehealth companies for false or misleading claims about compounded GLP-1 products on their websites.[1]

What the letters targeted

FDA said the main violations were claims implying that compounded products are the same as FDA-approved products, and branding that implied the telehealth company was the compounder.[1] Its guidance for telehealth companies also lists calling a compounded drug a generic, claiming FDA approval, claiming it is clinically proven to match the approved drug, and claiming it comes from an “FDA-approved” pharmacy, since FDA does not approve or license facilities.[2]

Context

FDA described this as the second group of telehealth letters since a September 2025 crackdown on misleading direct-to-consumer drug ads, and said it had sent thousands of such letters in six months.[1] A warning letter is a regulatory notice to a company. It is not a recall and is not a ruling about any individual’s treatment.

References

  1. U.S. Food and Drug Administration. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s. Press announcement, March 3, 2026. https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s. Checked October 15, 2026.
  2. U.S. Food and Drug Administration. FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs. Content current as of June 15, 2026. https://www.fda.gov/drugs/human-drug-compounding/fda-telehealth-companies-what-know-when-promoting-compounded-drugs. Checked October 15, 2026.

This page summarizes published research and regulatory documents. It is not medical advice and does not recommend starting, stopping, or changing any medication.